Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma

卡波扎尼布 舒尼替尼 医学 克里唑蒂尼 临床终点 内科学 危险系数 乳头状肾细胞癌 肿瘤科 肾细胞癌 阿西替尼 帕唑帕尼 临床试验 泌尿科 置信区间 肺癌 恶性胸腔积液
作者
Pedro C. Barata,Catherine M. Tangen,Melissa Plets,Ian M. Thompson,Vivek Narayan,Daniel J. George,Daniel Yick Chin Heng,Brian Shuch,Mark N. Stein,Shuchi Gulati,Maria Tretiakova,Abhishek Tripathi,Georg A. Bjarnason,Peter A. Humphrey,Adebowale Adeniran,Ulka N. Vaishampayan,Ajjai Alva,Tian Zhang,Scott Cole,Primo N. Lara,Seth P. Lerner,Naomi B. Haas,Sumanta K. Pal
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
标识
DOI:10.1200/jco.24.00767
摘要

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Mesenchymal-epithelial transition (MET) signaling pathway plays a role in the pathogenesis of selected patients with papillary renal cell carcinoma (PRCC). In the phase II PAPMET trial (ClinicalTrials.gov identifier: NCT02761057 ), cabozantinib significantly prolonged progression-free survival and improved objective response rate compared with sunitinib in patients with advanced PRCC. Here, we present the final overall survival (OS) analysis. In this multicenter, randomized phase II, open-label trial, 147 patients with advanced PRCC who have received up to one previous therapy (excluding vascular endothelial growth factor–directed agents) were assigned to sunitinib, cabozantinib, crizotinib, or savolitinib. Ultimately, savolitinib and crizotinib arms were closed because of futility. With a median follow-up of 17.5 months, the median OS was 21.5 months (95% CI, 12.0 to 28.1) with cabozantinib and 17.3 months (95% CI, 12.8 to 21.8) with sunitinib (hazard ratio, 0.83; 95% CI, 0.51 to 1.36; P = .46). The OS landmark estimates for cabozantinib and sunitinib were 50% versus 39% at 24 months and 32% versus 28% at 36 months. In conclusion, we observed no significant difference in OS across treatment arms. Although cabozantinib represents a well-supported option for advanced PRCC, the lack of survival benefit underscores the need to develop novel therapies for this disease.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
MHCL完成签到 ,获得积分10
1秒前
哈基米德应助一颗小番茄采纳,获得30
1秒前
矮小的天菱完成签到,获得积分10
2秒前
长安发布了新的文献求助10
2秒前
5秒前
ddddddd完成签到,获得积分20
6秒前
章半仙完成签到,获得积分10
7秒前
8秒前
10秒前
amberzyc应助小远采纳,获得10
11秒前
qiongqiong完成签到,获得积分10
12秒前
淡定的依瑶完成签到,获得积分10
13秒前
江璃发布了新的文献求助10
15秒前
16秒前
17秒前
美丽的安珊完成签到,获得积分10
18秒前
18秒前
20秒前
Gilana完成签到,获得积分10
20秒前
xyh发布了新的文献求助10
20秒前
江璃完成签到,获得积分10
21秒前
TT发布了新的文献求助10
21秒前
美梦成真完成签到,获得积分10
22秒前
Gakay完成签到,获得积分10
22秒前
量子星尘发布了新的文献求助10
23秒前
szj完成签到,获得积分0
24秒前
旦皋完成签到,获得积分10
24秒前
赘婿应助花壳在逃野猪采纳,获得10
25秒前
卷卷完成签到,获得积分10
27秒前
JSY完成签到 ,获得积分20
27秒前
xyh完成签到,获得积分10
28秒前
小曾应助Florencia采纳,获得10
29秒前
神外王001完成签到 ,获得积分10
29秒前
34秒前
你是谁完成签到,获得积分10
35秒前
majf完成签到,获得积分10
36秒前
linhanwenzhou完成签到,获得积分10
36秒前
JSY关注了科研通微信公众号
36秒前
853225598完成签到,获得积分10
36秒前
798完成签到,获得积分10
37秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038368
求助须知:如何正确求助?哪些是违规求助? 3576068
关于积分的说明 11374313
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029